(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of ...
Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...
CORT team has identified key biomarkers and treatment strategies that predict and enhance effectiveness of radiotherapy in ...
Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...
CHANGSHA -- Chinese researchers have successfully extracted high-purity lead-212 and bismuth-212 nuclides from rare earth ...
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...
AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...
AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...
Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...
His insurance agent told him he’d first have to be screened for prostate cancer, which would require him to provide a blood sample that would be tested for the presence of prostate-specific antigen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback